Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.

Molecular cancer therapeutics - 1 Aug 2013

Saito Ken, Takigawa Nagio, Ohtani Naoko, Iioka Hidekazu, Tomita Yuki, Ueda Ryuzo, Fukuoka Junya, Kuwahara Kazuhiko, Ichihara Eiki, Kiura Katsuyuki, Kondo Eisaku

Abstract excerpt

Activation of the epidermal growth factor receptor (EGFR) has been observed in many malignant tumors and its constitutive signal transduction facilitates the proliferation of tumors. EGFR-tyrosine kinase inhibitors, such as gefitinib, are widely used as a molecular-targeting agent for the inactivation of EGFR signaling and show considerable therapeutic effect in non-small cell lung cancers harboring activating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gefitinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Intracellular Space

Share to Peptides

Share to Protein Kinase Inhibitors

Share to Protein Transport

Share to Quinazolines

Share to Tumor Suppressor Protein p14ARF

Source

Identifiers

PMID: 23761220
DOI: 10.1158/1535-7163.MCT-12-1239

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.PMID 23761220Read ↗

p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.Semantic proximity Read ↗

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.Semantic proximity Read ↗

Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.Semantic proximity Read ↗

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathwaySemantic proximity Read ↗

Dual Role of the Alternative Reading Frame ARF Protein in CancerSemantic proximity Read ↗

Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.Semantic proximity Read ↗

Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.Semantic proximity Read ↗

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.Semantic proximity Read ↗

Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1Semantic proximity Read ↗

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.Semantic proximity Read ↗

Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.